The landmark randomized KATHERINE trial involved 1486 patients with HER2 positive early breast cancer, who were found to have residual invasive disease in the breast or axilla at surgery following neoadjuvant therapy with taxanes (with or without anthracycline) and trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.